

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail: investors@ipca.com Website : www.ipca.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		Dec 31, 2019	Sept 30, 2019	Dec 31, 2018	Dec 31, 2019	Dec 31, 2018	March 31, 2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	1139.07	1212.56	947.59	3362.64	2799.34	3633.15
II	Other Income	17.63	14.33	12.63	51.39	40.01	54.59
III	Total Income (I+II)	1156.70	1226.89	960.22	3414.03	2839.35	3687.74
IV	Expenses						
	a) Cost of materials consumed	350.63	387.77	294.18	1060.04	831.88	1098.02
	b) Purchases of stock-in-trade	53.98	53.91	40.80	153.80	123.83	167.87
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(23.08)	(32.02)	(35.27)	(60.08)	(64.93)	(106.14)
	d) Employee benefits expense	217.72	219.69	176.25	642.91	575.42	752.24
	e) Finance costs	3.80	4.05	4.93	12.32	12.24	18.49
	f) Depreciation and amortisation expense	46.16	45.11	42.62	133.31	130.27	171.88
	g) Other expenses	274.38	321.65	239.93	843.93	814.64	1027.99
	Total Expenses (IV)	923.59	1000.16	763.44	2786.23	2423.35	3130.35
V	Profit before exceptional items and tax (III-IV)	233.11	226.73	196.78	627.80	416.00	557.39
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V-VI)	233.11	226.73	196.78	627.80	416.00	557.39
VIII	Tax Expense						
	-Current tax	40.78	32.52	42.30	109.80	89.00	119.90
	-Short / (Excess) provision of earlier years	-	-	(0.03)	-	(5.02)	(5.02)
	-Deferred tax liability / (asset) including MAT credit	(4.30)	(1.81)	(5.67)	(6.70)	(13.42)	(12.40)
IX	Profit for the period from continuing operations (VII-VIII)	196.63	196.02	160.18	524.70	345.44	454.91
X	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss -						
	- Actuarial gain/(loss)	(0.61)	(3.61)	-	(4.57)	3.27	(1.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.11	0.61	-	0.80	(0.70)	0.30
	B (i) Items that will be reclassified to profit or loss						
	- Exchange difference in translating the financial statement of foreign operation	0.23	(0.15)	(0.39)	0.02	(0.38)	(0.64)
	- Gain/(loss) on cash flow hedge	0.12	(0.14)	(0.81)	(0.71)	(3.05)	(3.41)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.04)	-	-	0.12	-	-
	Other Comprehensive Income / (Loss) for the period net of tax (X)	(0.19)	(3.29)	(1.20)	(4.34)	(0.86)	(5.14)
XI	Total Comprehensive Income for the period (IX+X)	196.44	192.73	158.98	520.36	344.58	449.77
XII	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.27	25.27	25.27	25.27
XIII	Other Equity	-	-	-	-	-	3111.39
XIV	Net Worth	-	-	-	-	-	3136.66
XV	Earnings per share (of ₹ 2/- each) (Not annualised):						
	Basic (₹)	15.56	15.51	12.68	41.53	27.34	36.01
	Diluted (₹)	15.56	15.51	12.68	41.51	27.34	36.01

- Notes:
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 12, 2020. The Statutory Auditors have carried out the limited review of the results.
 - The Board has declared an interim dividend of ₹ 5/- per share (250%), for which February 20, 2020 has been fixed as the record date for members' entitlement of interim dividend.
 - The Company has only one operating segment viz: 'Pharmaceuticals'.
 - Figures of the previous periods have been regrouped wherever necessary.

SIGNED FOR IDENTIFICATION
BY
G. M. Kapadia
G. M. KAPADIA & CO.
MUMBAI.



By Order of the Board
For Ipca Laboratories Limited

Prerchand Gotha
Prerchand Gotha
Chairman & Managing Director
(DIN 00012691)

Place : Mumbai,
Date : February 12, 2020

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837


Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Nine months Ended		Year Ended
		Dec 31, 2019	Sept 30, 2019	Dec 31, 2018	Dec 31, 2019	Dec 31, 2018	March 31, 2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	1,212.86	1,283.90	1,006.14	3,574.95	2,893.57	3,773.18
II	Other income	18.13	14.80	13.34	53.27	42.42	57.68
III	Total income (I+II)	1,230.99	1,298.70	1,019.48	3,628.22	2,935.99	3,830.86
IV	Expenses :						
	a) Cost of materials consumed	359.92	393.86	295.61	1,082.69	837.63	1,106.08
	b) Purchases of stock-in-trade	96.68	92.82	73.34	274.37	156.85	249.07
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(32.79)	(36.95)	(30.08)	(77.52)	(61.44)	(115.42)
	d) Employee benefits expense	231.30	232.04	185.70	679.05	600.30	787.40
	e) Finance costs	4.01	4.23	5.12	12.83	12.43	18.87
	f) Depreciation and amortisation expense	50.83	49.63	45.74	146.56	137.66	182.42
	g) Other expenses	284.09	336.27	247.11	878.12	832.93	1,054.17
	Total Expenses (IV)	994.04	1,071.80	822.54	2,996.10	2,516.36	3,282.59
V	Profit from ordinary activity before share of profit of associates & joint venture, exceptional items & tax (III - IV)	236.95	226.80	196.94	632.12	419.63	548.27
VI	Share of Profit / (loss) of associates & joint venture accounted by using the equity method	(2.52)	(1.37)	(0.41)	(5.48)	(0.84)	(1.81)
VII	Profit before exceptional items and tax (V+VI)	234.43	225.43	196.53	626.64	418.79	546.46
VIII	Exceptional items	-	-	-	-	-	-
IX	Profit before tax (VII - VIII)	234.43	225.43	196.53	626.64	418.79	546.46
X	Tax Expense						
	-Current tax	40.95	33.28	43.05	111.68	90.83	121.81
	-Short / (Excess) provision of earlier years	-	0.19	(0.03)	0.19	(5.02)	(5.44)
	-Deferred tax liability / (asset) including MAT credit	(4.06)	(1.58)	(5.60)	(5.74)	(13.22)	(12.13)
XI	Profit for the period from continuing operations (IX-X)	197.54	193.54	159.11	520.51	346.20	442.22
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss -						
	-Actuarial gain/(loss)	(0.61)	(3.61)	-	(4.57)	3.27	(1.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.11	0.61	-	0.80	(0.70)	0.30
	B. (i) Items that will be reclassified to profit or loss						
	- Exchange difference in translating the financial statement of foreign operation	4.06	3.06	(6.52)	7.17	2.00	1.07
	-Gain/(loss) on cash flow hedge	0.12	(0.14)	(0.81)	(0.71)	(3.05)	(3.41)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.04)	-	-	0.12	-	-
	C. Share of OCI from investment in associates	(0.13)	(0.12)	(0.08)	(0.37)	(0.24)	(0.40)
	Other Comprehensive Income / (Loss) for the period, net of tax	3.51	(0.20)	(7.41)	2.44	1.28	(3.83)
XIII	Total Comprehensive Income for the period (XI + XII)	201.05	193.34	151.70	522.95	347.48	438.39
	Profit for the period attributable to :						
	Owners of the parent	197.61	193.07	159.19	520.31	346.28	444.83
	Non-controlling interest - profit / (loss)	(0.07)	0.47	(0.08)	0.20	(0.08)	(2.61)
		197.54	193.54	159.11	520.51	346.20	442.22
	Other Comprehensive Income for the period attributable to :						
	Owners of the parent	3.43	(0.27)	(8.05)	2.04	0.64	(3.08)
	Non-controlling interest - profit / (loss)	0.08	0.07	0.64	0.40	0.64	(0.75)
		3.51	(0.20)	(7.41)	2.44	1.28	(3.83)
	Total Comprehensive Income for the period attributable to :						
	Owners of the parent	201.04	192.80	151.14	522.35	346.92	441.75
	Non-controlling interest - profit / (loss)	0.01	0.54	0.56	0.60	0.56	(3.36)
		201.05	193.34	151.70	522.95	347.48	438.39
XIV	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.27	25.27	25.27	25.27
XV	Other Equity	-	-	-	-	-	3,097.12
XVI	Net Worth	-	-	-	-	-	3,122.38
XVII	Earning per equity share (of ₹ 2/- each) (Not annualised):						
	Basic (₹)	15.63	15.32	12.59	41.20	27.40	35.01
	Diluted (₹)	15.63	15.32	12.59	41.18	27.40	35.01

SIGNED FOR IDENTIFICATION
BY *G.M. Kapadia*
G. M. KAPADIA & CO.
MUMBAI.



Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 12, 2020. The Statutory Auditors have carried out the limited review of the results for the quarters and nine months ended December 31, 2019 only. The financial results and other financial information for the quarter and nine months ended December 31, 2018 have not been subjected to limited review/audit. However, the management has exercised due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 2 The Board has declared an interim dividend of ₹ 5/- per share (250%), for which February 20, 2020 has been fixed as the record date for member's entitlement of interim dividend.
- 3 The Group has only one operating segment viz. 'Pharmaceuticals'.
- 4 Figures of the previous periods have been regrouped wherever necessary.

Place : Mumbai,
Date : February 12, 2020

SIGNED FOR IDENTIFICATION
BY *G.M. Kapadia*
G. M. KAPADIA & CO.
MUMBAI.



By Order of the Board
For Ipca Laboratories Limited

Premchand Godha

Premchand Godha
Chairman & Managing Director
(DIN 00012691)

PRESS RELEASE

Ipca Laboratories Q3 FY20 Financial Results

Mumbai, February 12, 2020 : Ipca Laboratories Limited today announced its unaudited consolidated financial results for the third quarter and nine months ended 31st December, 2019.

Key Financials of Q3 FY20

- Standalone Net total Income up 20% at Rs. 1156.70 crores.
- Consolidated Net total Income up 21% at Rs. 1230.99 crores.
- Indian formulations income up 15% at Rs. 485.63 crores.
- Exports Income up 25% at Rs. 585.61 crores.
- Standalone EBITDA margin (before forex (gain)/loss) @ 24.46% in Q3 FY20 as against @ 22.48% in Q3 FY19.
- Consolidated EBITDA margin @ 23.56% in Q3 FY20 as against @ 20.72% in Q3 FY19.
- Standalone Net Profit at Rs. 196.63 crores up 23%.
- Consolidated Net Profit at Rs. 197.54 crores up 24%.
- The Board has declared an Interim Dividend of Rs. 5/- per share (250%) .

Standalone Q3 FY20 at a glance			(Rs. Crores)
Particulars	Q3 FY20	Q3 FY19	Growth
Net Total Income	1156.70	960.22	20%
Export Income	585.61	467.95	25%
EBITDA before Forex (gain) / loss	282.94	215.86	31%
Forex (gain) / loss	(0.13)	(28.47)	-
Finance Cost	3.80	4.93	-23%
Depreciation and Amortisation	46.16	42.62	8%
Tax Expense	36.48	36.60	-
Net Profit after tax	196.63	160.18	23%
Earnings per share of Rs. 2/- each (Rs.)	15.56	12.68	23%

Consolidated Q3 FY20 at a glance			(Rs. Crores)
Particulars	Q3 FY20	Q3 FY19	Growth
Consolidated Net Total Income	1230.99	1019.48	21%
Consolidated EBITDA before Forex (gain) / loss	290.03	211.26	37%
Share of (profit) / loss of associates & joint venture	2.52	0.41	-
Forex (gain) / loss	(1.76)	(36.54)	-
Finance Cost	4.01	5.12	-22%
Depreciation and Amortisation	50.83	45.74	11%
Tax Expense	36.89	37.42	-1%
Consolidated Net Profit after tax	197.54	159.11	24%
Consolidated Earnings per share of Rs. 2/- each (Rs.)	15.63	12.59	24%



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Q3 FY20 Revenue break-up		(Rs. Crores)	
Particulars	Q3 FY20	Q3 FY19	Growth
Formulations			
Domestic	485.63	421.57	15%
Exports			
Branded	112.98	104.58	8%
Institutional	47.82	38.85	23%
Generics	192.63	138.96	39%
Total Formulations	839.06	703.96	19%
APIs			
Domestic	53.18	44.50	20%
Exports	232.18	185.56	25%
Total APIs	285.36	230.06	24%
Other Operating Income	14.65	13.57	8%
Standalone Revenue from Operations	1139.07	947.59	20%
Revenue from Operations – Subsidiaries	73.79	58.55	26%
Consolidated Revenue from Operations	1212.86	1006.14	21%
Other Income	18.13	13.34	36%
Consolidated Net Total Income	1230.99	1019.48	21%

Key Financials of 9 months FY20

- Standalone Net Total Income up 20% at Rs. 3414.03 crores.
- Consolidated Net Total Income up 24% at Rs. 3628.22 crores.
- Indian formulations income up 15% at Rs. 1481.65 crores.
- Exports Income up 26% at Rs. 1651.09 crores.
- Standalone EBITDA margin (before forex (gain) / loss) @ 22.45% in 9 months FY20 as against @ 20.62% in 9 months FY19
- Consolidated EBITDA margin @ 21.58% in 9 months FY20 as against @ 20.04% in 9 months FY19
- Standalone Net Profit at Rs. 524.70 crores up 52%.
- Consolidated Net Profit at Rs. 520.51 crores up 50%

Standalone Nine Months FY20 at a glance		(Rs. Crores)	
Particulars	9 months FY20	9 months FY19	Growth
Net Total Income	3414.03	2839.35	20%
Export Income	1651.09	1311.68	26%
EBITDA before Forex (gain) / loss	766.51	585.36	31%
Forex (gain) / loss	(6.92)	26.85	-
Finance Cost	12.32	12.24	1%
Depreciation and Amortisation	133.31	130.27	2%
Tax Expense	103.10	70.56	46%
Net Profit after tax	524.70	345.44	52%
Earnings per share of Rs. 2/- each (Rs.)	41.53	27.34	52%



ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444


E: ipca@ipca.com CIN: L24239MH1949PLC007837


Consolidated Nine Months FY20 at a glance			(Rs. Crores)
Particulars	9 months FY20	9 months FY19	Growth
Consolidated Net Total Income	3628.22	2935.99	24%
Consolidated EBITDA before Forex (gain) / loss	782.95	588.40	33%
Share of (profit) / loss of associates & joint venture	5.48	0.84	-
Forex (gain) / loss	(8.56)	18.68	-
Finance Cost	12.83	12.43	3%
Depreciation and Amortisation	146.56	137.66	6%
Tax Expense	106.13	72.59	46%
Consolidated Net Profit after tax	520.51	346.20	50%
Consolidated Earnings per share of Rs. 2/- each (Rs.)	41.20	27.40	50%

Nine Months FY20 Revenue break-up			(Rs. Crores)
Particulars	9 months FY20	9 months FY19	Growth
<u>Formulations</u>			
Domestic	1481.65	1291.13	15%
<u>Exports</u>			
Branded	304.81	266.35	14%
Institutional	136.60	124.13	10%
Generics	497.67	404.18	23%
Total Formulations	2420.73	2085.79	16%
<u>APIs</u>			
Domestic	186.05	155.94	19%
Exports	712.01	517.02	38%
Total APIs	898.06	672.96	33%
Other Operating Income	43.85	40.59	8%
Standalone Revenue from Operations	3362.64	2799.34	20%
Revenue from Operations – Subsidiaries	212.31	94.23	125%
Consolidated Revenue from Operations	3574.95	2893.57	24%
Other Income	53.27	42.42	26%
Consolidated Net Total Income	3628.22	2935.99	24%

About Ipca Laboratories:

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 48% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.


 Premchand Godha
 Chairman & Managing Director



Encl: Unaudited Standalone Financial Results

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22- 6210 6050

Ipca Laboratories Ltd.
www.ipca.com